Payment overview · 2025
General Payments
$4,283.28
163 reported records · 21 companies
Healthcare provider profile · identity verified
Joseph C Morelos, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · LAKEWOOD, NJ · NPI 1861498693
Verified facts
What the public records show
CMS Open Payments records show Joseph C Morelos, D.O. received $4,283.28 in general payments during 2025 across 163 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lantus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,196.30 | 27.9% | 27 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $507.96 | 11.9% | 25 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $422.31 | 9.9% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $413.14 | 9.7% | 14 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $233.69 | 5.5% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $226.49 | 5.3% | 7 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $220.20 | 5.1% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $196.55 | 4.6% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $158.32 | 3.7% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $131.16 | 3.1% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $122.28 | 2.9% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $94.27 | 2.2% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $75.97 | 1.8% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.28 | 1.6% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $65.75 | 1.5% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $53.37 | 1.2% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $20.95 | 0.5% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $20.88 | 0.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.76 | 0.4% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $18.66 | 0.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.99 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,283.28 | 163 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $601.76 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $416.19 | 20 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $363.20 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $276.41 | 18 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $261.94 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $249.33 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $249.10 | 15 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $233.69 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $231.31 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $189.76 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $189.76 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $163.81 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $153.54 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $142.69 | 8 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $122.28 | 5 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $112.04 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $112.04 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $108.16 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $101.49 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $91.77 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $87.09 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $87.09 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $87.09 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $75.97 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $75.82 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $70.28 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $65.75 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $53.37 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.81 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.60 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.60 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $33.63 | 2 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $6.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 161 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 60 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 133 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
133 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
161 | 45 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 852 | 220 |
| Levothyroxine Sodium | Levothyroxine Sodium | 470 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 463 | 148 |
| Alprazolam | Alprazolam | 360 | 91 |
| Metformin Hcl | Metformin Hcl | 320 | 91 |
| Losartan Potassium | Losartan Potassium | 307 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 273 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 85 |
| Lisinopril | Lisinopril | 254 | 76 |
| Escitalopram Oxalate | Escitalopram Oxalate | 247 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 199 | 62 |
| Simvastatin | Simvastatin | 196 | 53 |
| Furosemide | Furosemide | 185 | 62 |
| Montelukast Sodium | Montelukast Sodium | 183 | 63 |
| Gabapentin | Gabapentin | 165 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 48 |
| Eliquis | Apixaban | 161 | 45 |
| Lorazepam | Lorazepam | 156 | 24 |
| Carvedilol | Carvedilol | 152 | 46 |
| Omeprazole | Omeprazole | 148 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 37 |
| Glimepiride | Glimepiride | 147 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 27 |
| Mounjaro | Tirzepatide | 133 | 25 |
| Ezetimibe | Ezetimibe | 128 | 36 |
| Mirtazapine | Mirtazapine | 124 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 120 | 98 |
| Trazodone Hcl | Trazodone Hcl | 111 | 32 |
| Tramadol Hcl | Tramadol Hcl | 104 | 31 |
| Valsartan | Valsartan | 98 | 31 |
| Allopurinol | Allopurinol | 95 | 22 |
| Xarelto | Rivaroxaban | 91 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 26 |
| Donepezil Hcl | Donepezil Hcl | 90 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 38 |
| Januvia | Sitagliptin Phosphate | 81 | 18 |
| Sertraline Hcl | Sertraline Hcl | 77 | 27 |
| Amoxicillin | Amoxicillin | 72 | 52 |
| Finasteride | Finasteride | 72 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 71 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 18 |
| Divalproex Sodium | Divalproex Sodium | 69 | suppressed |
| Glipizide | Glipizide | 69 | 19 |
| Diazepam | Diazepam | 66 | 13 |
| Synthroid | Levothyroxine Sodium | 66 | 17 |
| Temazepam | Temazepam | 63 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 43 |
| Farxiga | Dapagliflozin Propanediol | 60 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 14 |
| Azithromycin | Azithromycin | 58 | 50 |
| Ramipril | Ramipril | 56 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Potassium Chloride | Potassium Chloride | 55 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 54 | 37 |
| Celecoxib | Celecoxib | 53 | 22 |
| Bupropion Xl | Bupropion Hcl | 52 | 18 |
| Prednisone | Prednisone | 51 | 23 |
| Clonazepam | Clonazepam | 50 | 13 |
| Irbesartan | Irbesartan | 50 | 15 |
| Enalapril Maleate | Enalapril Maleate | 49 | 15 |
| Atenolol | Atenolol | 48 | 16 |
| Cefuroxime | Cefuroxime Axetil | 48 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 20 |
| Buspirone Hcl | Buspirone Hcl | 47 | 17 |
| Famotidine | Famotidine | 45 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 11 |
| Ozempic | Semaglutide | 42 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 39 |
| Repaglinide | Repaglinide | 41 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 11 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 36 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 16 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | 11 |
| Naproxen | Naproxen | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Glyburide | Glyburide | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Nystatin | Nystatin | 27 | 19 |
| Nifedipine Er | Nifedipine | 26 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 18 |
| Veltassa | Patiromer Calcium Sorbitex | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | 14 |
| Ampicillin Sodium | Ampicillin Sodium | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 24 |
| Promethazine Hcl | Promethazine Hcl | 24 | 15 |
| Torsemide | Torsemide | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | 12 |
| Telmisartan | Telmisartan | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | 13 |
| Nuplazid | Pimavanserin Tartrate | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,283.28 · 163 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, ELIQUIS, EVENITY, EVKEEZA, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LOKELMA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QSYMIA, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAQEL, Wegovy, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error